ReviewMaterials today. Bio2025
Advances in targeted therapy for tumor with nanocarriers: A review.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Bio-based nanomaterials in drug delivery: An updated review.Pharmaceutical science advances · 2026Review
- Engineering Polymeric Nano-PROTAC for Targeted Protein Degradation and Cancer Therapy.Polymer science & technology (Washington, D.C.) · 2026Review
- Stimuli-Responsive Nanocarriers as Next-Generation on-Demand Drug Delivery Systems for Cancer Therapy: Mechanistic Insights, Trigger Modalities, and Translational Challenges.Pharmaceutics · 2026Review
- Therapeutic strategies for ischemic heart disease with natural product-based nanomedicines.Journal of nanobiotechnology · 2026Review
- Tumor-targeted liposomal RNAi therapy suppresses breast cancer and modulates tumor microenvironment.Journal of nanobiotechnology · 2026Article
- Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026Review
- An exosome-biomimetic photothermal nanocarrier for IGF2BP2 siRNA delivery and enhanced ferroptosis in head and neck squamous cell carcinoma.Materials today. Bio · 2026Article
- Design, Synthesis, and Self-Assembly of Amphiphilic 1,4-Dihydropyridines Containing Branched Ester Moieties.Molecules (Basel, Switzerland) · 2026Article
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- A mitochondrion-targeted natural polyphenolic copper carrier overcomes tumor resistance to cisplatin by potentiating cuproptosis.Journal of experimental & clinical cancer research : CR · 2026Article
- Magnetic Nanocarriers with ICPTES- and GPTMS-Functionalized Quaternary Chitosan for pH-Responsive Doxorubicin Release.Biomolecules · 2026Article
- EGCG-Building Nanocarriers for Multitasking Drug Delivery: Design Principles, Therapeutic Opportunities, and Translational Challenges.International journal of nanomedicine · 2026Review
- Bridging bioactive metabolites ofFrontiers in pharmacology · 2026Review
- Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in Breast Cancer.Current pharmaceutical design · 2026Review
- Advancements in Nanoparticle-Based Therapies for Breast Cancer: Current Trends and Future Prospects.International journal of breast cancer · 2026Review
- Advances in nanotechnology for early cancer diagnosis: emerging nanoplatforms and multimodal imaging approaches.American journal of cancer research · 2026Review
- A Dual-Stimuli Responsive Nanoplatform via Atomic Layer Deposition of Gold on CoFeInternational journal of nanomedicine · 2026Article
- Rethinking delivery routes: oral administration of plant-derived exosome-like nanovesicles reduces the toxicity of intravenous injection.Extracellular vesicles and circulating nucleic acids · 2026Article
- Engineering biopolymer nanoparticles for targeted nanomedicine in cancer therapy and food preservation.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of Nanocarriers (NCs) provides a promising strategy to solve the problems faced by traditional chemotherapy drugs, like the imprecise delivery, poor bioavailability, high dose requirement, and the tendency to develop multidrug resistance. With the protection of NCs, chemotherapy drugs can reach the lesion site and then release accurately and completely. Although some reviews have summarized the biological applications of NCs, little attention has been given to the advantages and disadvantages of analyzing organic, inorganic, and hybrid NCs separately for targeted therapy and identifying means to further improve the targeting ability. First, in this review, we emphasize three factors that have a marked impact on targeted therapy: the tumor microenvironment (TME), the different administration modalities (intravenous, oral, and intracavitary administration), and the targeting pathways (passive and active). Second, a systematic examination of the advantages and disadvantages of polymeric NCs, dendrimers, micelles, liposomes, mesoporous silica NCs, gold NCs, quantum dots, nano clay, core-shell NCs, and MOFs for targeted therapy are reviewed. Further, we propose three ways to improve the efficiency of targeted therapy, including regulating the size, shape, and surface properties of NCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.